301 related articles for article (PubMed ID: 20614444)
21. Treatment of pediatric heterozygous familial hypercholesterolemia 7 years after the EAS recommendations: Real-world results from a large French cohort.
Peretti N; Vimont A; Mas E; Lemale J; Reynaud R; Tounian P; Poinsot P; Restier L; Paillard F; Pradignac A; Pucheu Y; Rabès JP; Bruckert E; Gallo A; Béliard S
Arch Pediatr; 2024 Apr; 31(3):188-194. PubMed ID: 38538465
[TBL] [Abstract][Full Text] [Related]
22. Are treatment targets for hypercholesterolemia evidence based? Systematic review and meta-analysis of randomised controlled trials.
Lebenthal Y; Horvath A; Dziechciarz P; Szajewska H; Shamir R
Arch Dis Child; 2010 Sep; 95(9):673-80. PubMed ID: 20515970
[TBL] [Abstract][Full Text] [Related]
23. The spectrum of statin therapy in hyperlipidemic children.
Rodenburg J; Vissers MN; Trip MD; Wiegman A; Bakker HD; Kastelein JJ
Semin Vasc Med; 2004 Nov; 4(4):313-20. PubMed ID: 15861313
[TBL] [Abstract][Full Text] [Related]
24. Familial hypercholesterolemia in children.
Rodenburg J; Vissers MN; Wiegman A; Trip MD; Bakker HD; Kastelein JJ
Curr Opin Lipidol; 2004 Aug; 15(4):405-11. PubMed ID: 15243213
[TBL] [Abstract][Full Text] [Related]
25. Systematic review and metaanalysis of statins for heterozygous familial hypercholesterolemia in children: evaluation of cholesterol changes and side effects.
O'Gorman CS; Higgins MF; O'Neill MB
Pediatr Cardiol; 2009 May; 30(4):482-9. PubMed ID: 19189168
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of combination therapy with ezetimibe and statins versus a double dose of statin monotherapy in participants with hypercholesterolemia: a meta-analysis of literature.
Yu M; Liang C; Kong Q; Wang Y; Li M
Lipids Health Dis; 2020 Jan; 19(1):1. PubMed ID: 31900179
[TBL] [Abstract][Full Text] [Related]
27. A meta-analysis to evaluate the efficacy of statins in children with familial hypercholesterolemia.
Shafiq N; Bhasin B; Pattanaik S; Pandhi P; Venkateshan SP; Singh M; Malhotra S
Int J Clin Pharmacol Ther; 2007 Oct; 45(10):548-55. PubMed ID: 17966840
[TBL] [Abstract][Full Text] [Related]
28. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease.
Stein EA; Dufour R; Gagne C; Gaudet D; East C; Donovan JM; Chin W; Tribble DL; McGowan M
Circulation; 2012 Nov; 126(19):2283-92. PubMed ID: 23060426
[TBL] [Abstract][Full Text] [Related]
29. Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?
Sbrana F; Dal Pino B; Bigazzi F; Ripoli A; Passino C; Gabutti A; Pasanisi EM; Petersen C; Valleggi A; Todiere G; Barison A; Giannoni A; Panchetti L; Becherini F; Pianelli M; Luciani R; Sampietro T
Eur J Prev Cardiol; 2017 Sep; 24(14):1528-1531. PubMed ID: 28555526
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia.
Avellone G; Di Garbo V; Guarnotta V; Scaglione R; Parrinello G; Purpura L; Torres D; Campisi D
Int Angiol; 2010 Dec; 29(6):514-24. PubMed ID: 21173733
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia.
Avis HJ; Hutten BA; Gagné C; Langslet G; McCrindle BW; Wiegman A; Hsia J; Kastelein JJ; Stein EA
J Am Coll Cardiol; 2010 Mar; 55(11):1121-6. PubMed ID: 20223367
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and Safety of Alirocumab in Japanese Patients With Heterozygous Familial Hypercholesterolemia or at High Cardiovascular Risk With Hypercholesterolemia Not Adequately Controlled With Statins - ODYSSEY JAPAN Randomized Controlled Trial.
Teramoto T; Kobayashi M; Tasaki H; Yagyu H; Higashikata T; Takagi Y; Uno K; Baccara-Dinet MT; Nohara A
Circ J; 2016 Aug; 80(9):1980-7. PubMed ID: 27452202
[TBL] [Abstract][Full Text] [Related]
33. Long-term follow-up of statin treatment in a cohort of children with familial hypercholesterolemia: efficacy and tolerability.
Carreau V; Girardet JP; Bruckert E
Paediatr Drugs; 2011 Aug; 13(4):267-75. PubMed ID: 21692550
[TBL] [Abstract][Full Text] [Related]
34. Intermediate-Term Efficacy and Tolerance of Statins in Children.
Mamann N; Lemale J; Karsenty A; Dubern B; Girardet JP; Tounian P
J Pediatr; 2019 Jul; 210():161-165. PubMed ID: 31053349
[TBL] [Abstract][Full Text] [Related]
35. Long-Term Cardiovascular Risk in Heterozygous Familial Hypercholesterolemia Relatives Identified by Cascade Screening.
Kjærgaard KA; Christiansen MK; Schmidt M; Olsen MS; Jensen HK
J Am Heart Assoc; 2017 Jun; 6(6):. PubMed ID: 28652386
[TBL] [Abstract][Full Text] [Related]
36. Dietary interventions (plant sterols, stanols, omega-3 fatty acids, soy protein and dietary fibers) for familial hypercholesterolaemia.
Malhotra A; Shafiq N; Arora A; Singh M; Kumar R; Malhotra S
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD001918. PubMed ID: 24913720
[TBL] [Abstract][Full Text] [Related]
37. Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia.
Santos RD; Ruzza A; Hovingh GK; Wiegman A; Mach F; Kurtz CE; Hamer A; Bridges I; Bartuli A; Bergeron J; Szamosi T; Santra S; Stefanutti C; Descamps OS; Greber-Platzer S; Luirink I; Kastelein JJP; Gaudet D;
N Engl J Med; 2020 Oct; 383(14):1317-1327. PubMed ID: 32865373
[TBL] [Abstract][Full Text] [Related]
38. Genetic diagnosis of familial hypercholesterolemia in a South European outbreed population: influence of low-density lipoprotein (LDL) receptor gene mutations on treatment response to simvastatin in total, LDL, and high-density lipoprotein cholesterol.
Chaves FJ; Real JT; García-García AB; Civera M; Armengod ME; Ascaso JF; Carmena R
J Clin Endocrinol Metab; 2001 Oct; 86(10):4926-32. PubMed ID: 11600564
[TBL] [Abstract][Full Text] [Related]
39. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.
Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Perkovic V; Hegbrant J; Strippoli GF
Cochrane Database Syst Rev; 2014 May; (5):CD007784. PubMed ID: 24880031
[TBL] [Abstract][Full Text] [Related]
40. Treatment of childhood hypercholesterolemia with HMG-CoA reductase inhibitors.
Duplaga BA
Ann Pharmacother; 1999 Nov; 33(11):1224-7. PubMed ID: 10573325
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
